



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

Audited Financial Results for the Quarter ended 31.03.2014

PART-I Particulars	Rs. In lacs				
	3 months ended 31.03.2014 Audited	3 months ended 31.12.2013 Unaudited	3 months ended 31.03.2013 Audited	12 Months ended 31.03.2014 Audited	12 Months ended 31.03.2013 Audited
<b>1 Income from operations</b>					
a Net sales/Income from Operations (Net of excise duty)	3128.08	3770.16	3813.31	14385.09	16646.45
b Other Operating Income					
Total Income from operations (net)	3128.08	3770.16	3813.31	14385.09	16646.45
<b>2 Expenses</b>					
a Cost of materials consumed	1047.14	1457.69	1327.06	5461.64	7091.87
b Purchases of stock-in-trade	565.48	305.49	207.49	1294.90	1069.51
c Changes in inventories of finished	-939.18	132.96	612.47	-285.94	454.84
d Employee benefits expenses	1022.02	913.54	912.47	3783.43	3725.46
e Depreciation and amortisation expense	68.51	73.90	64.53	282.54	270.76
f Other expenses	1061.74	660.96	572.86	3063.27	3299.35
Total expenses	2825.71	3544.54	3696.98	13599.84	15911.79
<b>3 Profit from Operations before Other Income, Finance Cost and Exceptional</b>					
4 Other Income	302.37	225.62	116.33	785.25	734.66
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	6.07	225.62	32.31	6.07	32.31
6 Finance Cost	308.44	225.62	148.64	791.32	766.97
7 Profit from ordinary activities after finance cost but before Exceptional	183.16	108.22	140.42	538.19	513.35
8 Exceptional Items					
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	125.28	117.40	8.22	253.13	253.62
10 Tax expense	3.08	28.48	-24.64	41.06	70.36
11 Net Profit/(Loss) from Ordinary Activities after tax (9-10)	122.20	88.92	32.86	212.07	183.26
12 Extraordinary items (net of tax expense Rs. lacs)					
13 Net Profit/(Loss) for the period (11-12)	122.20	88.92	32.86	212.07	183.26
14 Share of profit/(Loss) of associates					
15 Minority interest					
16 Net Profit/(Loss) after taxes, minority	122.20	88.92	32.86	212.07	183.26
17 Paid up Eq. Sh. Cap. (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr.				7298.31	7239.49
<b>19.i Earnings Per Share (before extraordinary items)</b>					
a. Basic (Rs.)	0.47	0.34	0.13	0.81	0.70
b. Diluted (Rs.)	0.47	0.34	0.13	0.81	0.70
<b>19.ii Earnings Per Share (after extraordinary items)</b>					
a. Basic (Rs.)	0.47	0.34	0.13	0.81	0.70
b. Diluted (Rs.)	0.47	0.34	0.13	0.81	0.70
<b>PART-II</b>					
<b>A PARTICULARS OF SHAREHOLDING</b>					
<b>1 Public Shareholding</b>					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
<b>2 Promoter and promoter group shareholding</b>					
<b>A Pledged / encumbered</b>					
- Number of shares					
- Percentage of shares (as a % of the total shareholding of Promoter and					
- Percentage of shares (as a % of the total share capital of the Company)					
<b>B Non - encumbered</b>					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%
<b>B INVESTOR COMPLAINTS</b>					
Pending at the beginning of the quarter	0	0	0		
Received during the quarter	40	18	39		
Disposed of during the quarter	40	18	39		
Remaining unresolved at the end of the	0	0	0		

**Notes**

- The Audited Financial Results for the Quarter ended 31.03.2014 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 30.05.2014.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

By Order of the Board  
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
 Chairman cum Managing Director

Place : New Delhi  
 Date : 30.05.2014

Company Identification No:- L74899DL1978PLC009181

The Board has recommended dividend of Rs 0.50/- per Equity share of Rs 5/- each.

For Jagsonpal Pharmaceuticals Ltd.




Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953  
 Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

## Statement of Assets and Liabilities

		Rs. In lacs		Rs. In lacs	
A	EQUITY AND LIABILITIES	As at 31.03.2014	As at 31.03.2013	As at 31.03.2014	As at 31.03.2013
1	Shareholders' funds				
	(a) Share Capital	1309.90	1309.90	5872.74	6064.85
	(b) Reserves and surplus	8548.97	8527.24	3.00	3.00
	Sub-total - Shareholders' funds	9858.87	9837.14	0.05	0.05
2	Share application money pending allotment	0.00	0.00	0.00	0.00
3	Minority interest	0.00	0.00	0.00	577.91
4	Non-current liabilities			6494.31	6645.81
	(a) Long term borrowings	0.00	32.05		
	(b) Deferred tax liabilities (net)	408.39	417.91	3058.92	3006.84
	(c) Other long term liabilities	0.00	0.00	4522.09	4220.16
	(d) Long term provisions	0.00	0.00	1260.42	1034.34
	Sub-total - Non-current liabilities	408.39	449.96	289.98	392.99
5	Current liabilities			0.00	0.00
	(a) Short term borrowing	3595.76	3308.65	9131.41	8654.33
	(b) Trade payables	508.45	650.52		
	(c) Other current liabilities	548.10	399.34		
	(d) Short term provisions	706.15	654.53		
	Sub-Total - Current liabilities	5358.46	5013.04		
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15625.72</b>	<b>15300.14</b>	<b>15625.72</b>	<b>15300.14</b>

For Jagsonpal Pharmaceuticals Limited



*Ran...*  
Director

X

**Auditor's Report on Quarterly/yearly Financial Results for 31.03.2014 of Jagsonpal  
Pharmaceuticals Limited Pursuant to the Clause 41 of the Listing Agreement**

To

Board of Directors of Jagsonpal Pharmaceuticals Limited

We have audited the quarterly financial results of Jagsonpal Pharmaceuticals Limited for the quarter ended 31.03.2014 and the year to date results for the period 01.04.2013 to 31.03.2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31.03.2014 as well as the year to date results for the period from 01.04.2013 to 31.03.2014

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of

shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For P.P.Thukral & Company  
Chartered Accountants

Place: New Delhi

Date: 30<sup>th</sup> May, 2014



*Suresh Sethi*  
Suresh Sethi  
Partner

FRN. 000632N

M.No. 89318

Certified True Copy  
For Jagsonpal Pharmaceuticals Ltd.

*[Signature]*  
Company Secretary